Author: Dino Mustafić

December 10, 2021 Off

Moderna’s Phase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains

By Dino Mustafić

Moderna today announced the first positive interim data from the Phase 1 study of the Company’s quadrivalent seasonal flu vaccine candidate, mRNA-1010, as it successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.

December 10, 2021 Off

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18y and above, across six countries.

December 7, 2021 Off

Medicago and GSK receive good news for its plant-based COVID-19 vaccine candidate

By Dino Mustafić

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have received positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline.